FENCFennec Pharmaceuticals Inc.

11.29USD-4.89%Mkt Cap: 395.91M $P/E:

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cispl…

Key Statistics

Company
Market Cap395.91M $
Enterprise Value356.76M $
Revenue (TTM)59.22M $
Gross Profit40.88M $
Net Income (TTM)-9.74M $
Revenue/Share1.847 USD
Last Price11.29 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCA31447P1009
Valuation
P/E (Trailing)
P/E (Forward)11.92
PEG1.47
EV/EBITDA-349.31
EV/Revenue6.02
P/S6.72
P/B9.37
EPS (TTM)-0.11
EPS (Forward)0.95
52W Range
5.65074% of range13.25
52W High13.25 USD
52W Low5.650 USD
Profitability
Gross Margin91.57%
Oper. Margin9.72%
EBITDA Margin-1.73%
Profit Margin-21.82%
ROE-27.46%
ROA-13.81%
Growth
Revenue Growth85.20%
Earnings Growth
Cash Flow & Leverage
Operating CF-12.47M $
CapEx (TTM)
FCF Margin1.81%
FCF Yield0.27%
Net Debt-41.25M $
Net Debt/EBITDA40.39
Balance Sheet
Debt/Equity0.00
Current Ratio5.85
Quick Ratio5.21
Book Value/Sh1.211 USD
Cash/Share1.176 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.67 USD
Upside (mean)+56.5%
Target Range16.00 USD20.00 USD
$16.00+56.5% to mean$20.00
# Analysts6
Ownership
Shares Out.35.07M
Float19.78M
Insiders14.31%
Institutions54.32%
Short Interest
Short Ratio4.1d
Short % Float2.03%
Short % Out.1.76%
Shares Short615.87K
Short (prev mo.)488.73K
Technical
SMA 5010.44 (+8.1%)
SMA 2008.418 (+34.1%)
Beta1.07
S&P 52W Chg18.16%
Avg Vol (30d)178.12K
Avg Vol (10d)264.70K
Technical Indicators
RSI (14)53.5
MACD0.4564
MACD Signal0.3928
MACD Hist.+0.0636
BB Upper12.78 USD
BB Middle10.82 USD
BB Lower8.857 USD
BB Width36.27%
ATR (14)0.7007 USD
Vol Ratio (20d)1.08x